154 related articles for article (PubMed ID: 15917702)
1. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study.
Soubrane C; Rixe O; Meric JB; Khayat D; Mouawad R
Melanoma Res; 2005 Jun; 15(3):199-204. PubMed ID: 15917702
[TBL] [Abstract][Full Text] [Related]
2. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.
Mouawad R; Rixe O; Meric JB; Khayat D; Soubrane C
Cytokines Cell Mol Ther; 2002; 7(4):151-6. PubMed ID: 14660055
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
4. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
Franzke A; Probst-Kepper M; Buer J; Duensing S; Hoffmann R; Wittke F; Volkenandt M; Ganser A; Atzpodien J
Br J Cancer; 1998 Jul; 78(1):40-5. PubMed ID: 9662248
[TBL] [Abstract][Full Text] [Related]
5. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma.
Tas F; Oguz H; Argon A; Duranyildiz D; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(3):241-6. PubMed ID: 16110135
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
[TBL] [Abstract][Full Text] [Related]
8. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
9. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population.
Li C; Liu J; Jiang L; Xu J; Ren A; Lin Y; Yao G
Medicine (Baltimore); 2021 Feb; 100(8):e24840. PubMed ID: 33663104
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
[TBL] [Abstract][Full Text] [Related]
11. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
12. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma.
Nemunaitis J; Fong T; Shabe P; Martineau D; Ando D
Cancer Invest; 2001; 19(3):239-47. PubMed ID: 11338880
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum M30 and M65 levels in melanoma.
Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
[TBL] [Abstract][Full Text] [Related]
14. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
16. Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.
Tartour E; Blay JY; Dorval T; Escudier B; Mosseri V; Douillard JY; Deneux L; Gorin I; Negrier S; Mathiot C; Pouillart P; Fridman WH
J Clin Oncol; 1996 May; 14(5):1697-703. PubMed ID: 8622090
[TBL] [Abstract][Full Text] [Related]
17. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.
Mouawad R; Benhammouda A; Rixe O; Antoine EC; Borel C; Weil M; Khayat D; Soubrane C
Clin Cancer Res; 1996 Aug; 2(8):1405-9. PubMed ID: 9816314
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
19. Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy.
Mouawad R; Antoine EC; Gil-Delgado M; Khayat D; Soubrane C
Melanoma Res; 2002 Aug; 12(4):343-8. PubMed ID: 12170183
[TBL] [Abstract][Full Text] [Related]
20. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
Desch A; Gebhardt C; Utikal J; Schneider SW
Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
